valu usd unless otherwis note
earli parti deliv ahead
view iqvia report strong result driven growth
technolog analyt solut segment compani also
book impress award next-gen offer
biotech compani key growth driver go forward
ep y/i vs estim street
revenu cc vs estim
street revenu beat driven
impress revenu growth technolog analyt solut
formerli commerci solut report revenu
organ cc report
revenu organ cc core
strength off-set miss contract sale medic solut
formerli integr engag servic report revenu
cc also rais guidanc rang
year provid guidanc expect ep
adjust ebitda
revenu
expect ep adjust
ebitda revenu
nextgen solut power growth iqvia award
worth new busi next-gen clinic develop solut
quarter bring total sinc merger win rate
offer track rang accord manag
roughli twice regular win rate compani addit
next-gen award biotech compani key segment
growth go forward manag note book growth
due increment volum rather price slightli less
half award fix fee expect manag
gradual achiev greater share fix fee give better
continu sell well believ mani investor underappreci
compani technology-bas product offer
adjust estim increas ep estim
growth analyt segment
segment decreas expect tax rate put estim
high end manag guidanc addit rais
adjust ebitda estim
revenu estim put
estim higher end guidanc well believ
nextgen sale could start posit inflect futur posit
maintain outperform maintain outperform rate
increas pt new ep
price prior trade day market close estimate unless otherwis note
iqvia creat octob merger
quintil im health busi oper
three segment research develop commerci
solut integr engag servic compani
provid outsourc real-world evid solut
biopharmaceut compani also provid solut
connect healthcar technology-en commerci
believ strateg benefit combin
two busi expect financi benefit
realiz time although like limit
increment benefit manag target
estim increment annual revenu growth
three year follow octob close
merger manag also expect achiev million
outperform rate believ
opportun deliv faster revenu growth cost
synergi fulli reflect share current
valuat believ share move higher compani
abl deliv better-than-expect cross-sal
valuat move higher reflect earn growth
sale cost-synergi project
bloomberg capit market estim upside/downside/target
price target share base price-to-earnings multipl
appli ep estim
modest premium share trade sinc
ipo slightli histor premium
multipl believ premium histor multipl
justifi given synergi im merger compani
uniqu posit posit view biopharma
upsid scenario price share
reflect ep ahead current estim
price-to-earnings multipl believ upsid could driven
stronger-than-expect cro revenu growth greater
cross-sal client well increas merger synergi
downsid scenario price share
reflect ep growth midpoint guidanc
current forecast price-to-earnings ratio
line histor price-to-earnings ratio share
metric
report
basi compani
like releas metric
basi
iqvia hold result varianc tabl act commentstechnolog analyt solut synthet real-world win top five pharma clientresearch develop solut ever quarterli book give good visibl go forwardcontract sale medic solut ebitda analyt highest margin three segmentsdeprec tax eq tax equiti equiti earn iqvia net non- iqvia non- net non- average basic weight average dilut remain share repurchas author iqvia hold inc
price target share base price-to-earnings multipl appli
ep estim modest premium share trade sinc
ipo slightli histor premium multipl believ
premium histor multipl justifi given synergi im merger
compani uniqu posit posit view biopharma spend price
target support outperform rate
risk rate price target
key risk biopharma spend trend execut merger integr project
sale cost synergi trend spend compani commerci solut
iqvia creat octob merger quintil im health
busi oper three segment research develop commerci solut
integr engag servic compani provid outsourc real-world
evid solut biopharmaceut compani compani also provid solut
connect healthcar technology-en commerci oper
revenu
revenu
sell gener administr
revenu
adjust estim conting consider
revenu
loss extinguish debt
incom incom tax equiti earn unconsolid affili
incom equiti earn unconsolid affili
equiti earn unconsolid affili
net incom attribut non-controlling interest
net incom attribut quintil transnat hold
sale busi
